A spin - off from Queen's University 7 years ago, the drug discovery and development company develops novel cytochrome P450s to generate improved therapies for skin diseases and cancer.
The researchers used a novel combination of methods including synchrotron - based X-ray fluorescence microscopy at ANL's Advanced Photon Source and high - resolution electron microscopy analyses at the Environmental Molecular Sciences Laboratory (EMSL) located at PNNL to characterize UO2 - cytochrome interaction.